These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15865753)
1. Multiple sclerosis. Boggild M; Ford H Clin Evid; 2004 Dec; (12):1843-60. PubMed ID: 15865753 [No Abstract] [Full Text] [Related]
2. Multiple sclerosis. Ford H; Nicholas R Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466 [No Abstract] [Full Text] [Related]
3. [Pharmacological treatment of multiple sclerosis]. Myhr KM Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616 [TBL] [Abstract][Full Text] [Related]
4. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
5. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
7. A practical approach to immunomodulatory therapy for multiple sclerosis. Burks JS Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681 [TBL] [Abstract][Full Text] [Related]
8. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705 [TBL] [Abstract][Full Text] [Related]
10. Combining two multiple sclerosis treatments has no clinical benefit, study finds. Anekwe L BMJ; 2013 Mar; 346():f1719. PubMed ID: 23491460 [No Abstract] [Full Text] [Related]
11. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. Lim ET; Giovannoni G Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671 [TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis. Boggild M; Ford H Clin Evid; 2003 Dec; (10):1566-81. PubMed ID: 15555161 [No Abstract] [Full Text] [Related]
13. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis. Mattson DH Semin Neurol; 2002 Mar; 22(1):17-25. PubMed ID: 12170390 [TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Pula JH; Javed A Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177 [TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis. Boggild M; Ford H Clin Evid; 2003 Jun; (9):1459-73. PubMed ID: 15366193 [No Abstract] [Full Text] [Related]
16. Multiple sclerosis. Treatment is shifting. Mayo Clin Health Lett; 2003 Jan; 21(1):6. PubMed ID: 12619619 [No Abstract] [Full Text] [Related]
17. Patient and family fact sheet. Current treatments for multiple sclerosis. Kernich CA Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335 [No Abstract] [Full Text] [Related]
18. Beta interferons for multiple sclerosis. Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969 [No Abstract] [Full Text] [Related]
19. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J; Lublin FD Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]